SCHEMBL30199417

SCHEMBL30199417

Fc1cc(Cl)ccc1CCOc1ccc2c(c1)CN(CC1C=CC=C[C@@H]1CC1CCO1)CC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 7/20 0.40
▸ HRH1 P35367 3/20 0.40
▸ CXCR3 P49682 1/20 0.36
▸ SLC2A1 P11166 1/20 0.34
▸ MCHR1 Q99705 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ MOGAT2 Q3SYC2 2/20 0.33
▸ GPR84 Q9NQS5 1/20 0.33
▸ GLP1R P43220 3/20 0.32
▸ HTR5A P47898 1/20 0.32
▸ PDE1B Q01064 1/20 0.32
▸ KCNH2 Q12809 1/20 0.32
▸ HTR1A P08908 1/20 0.32
▸ DRD2 P14416 1/20 0.32
▸ HTR2A P28223 1/20 0.32
▸ HTR7 P34969 1/20 0.32
▸ DRD3 P35462 1/20 0.32
▸ HTR2B P41595 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30199079 0.84 HRH3 (0.39) HRH3HRH1GPR84
SCHEMBL30199782 0.83 HRH3 (0.44) HRH3HRH1GPR84
SCHEMBL30200138 0.82 HRH3 (0.41) HRH3HRH1MCHR1GPR84KCNH2
SCHEMBL30199307 0.82 GLP1R (0.41) GLP1R
SCHEMBL30199309 0.81 HRH3 (0.44) HRH3HRH1GPR84
SCHEMBL30199470 0.81 HRH3 (0.39) HRH3HRH1GPR84
SCHEMBL30199641 0.81 S1PR1 (0.34) CXCR3DRD2HTR7
SCHEMBL30199664 0.81 GPR84 (0.44) HRH3HRH1GPR84
SCHEMBL30199409 0.81 KCNH2 (0.41) HRH3HRH1GPR84GLP1RKCNH2
SCHEMBL30199156 0.81 KCNH2 (0.41) HRH3HRH1GPR84GLP1RKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115594669-A Fused ring derivative and preparation method and medical application thereof 深圳信立泰药业股份有限公司(CN) 2023-01-13 — — CN disclosed
Send feedback